FOLH1 and metastatic prostate carcinoma: Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) labeled with the beta-emitting 177Lutetium is a novel treatment for metastatic prostate cancer, with pending registration in 3rd or 4th line metastatic castration-resistant prostate cancer (mCRPC) [3].